Cargando…
Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action
Chronic myeloid leukemia (CML) is caused by constitutively active fusion protein BCR-ABL1, and targeting ABL1 is a promising therapy option. Imatinib, dasatinib, and nilotinib have all been shown to work effectively in clinical trials. ABL1 mutations, particularly the T315I gate-keeper mutation, cau...
Autores principales: | Daniel, Julio Paulino, Mesquita, Felipe Pantoja, Da Silva, Emerson Lucena, de Souza, Pedro Filho Noronha, Lima, Luina Benevides, de Oliveira, Lais Lacerda Brasil, de Moraes, Maria Elisabete Amaral, Moreira-Nunes, Caroline de Fátima Aquino, Burbano, Rommel Mario Rodríguez, Zanatta, Geancarlo, Montenegro, Raquel Carvalho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452629/ https://www.ncbi.nlm.nih.gov/pubmed/36091760 http://dx.doi.org/10.3389/fphar.2022.952250 |
Ejemplares similares
-
Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer
por: Mesquita, Felipe Pantoja, et al.
Publicado: (2022) -
Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations
por: Machado, Caio Bezerra, et al.
Publicado: (2021) -
Genomic surveillance: Circulating lineages and genomic variation of SARS-CoV-2 in early pandemic in Ceará state, Northeast Brazil
por: Oliveira, Francisca Andréa da Silva, et al.
Publicado: (2022) -
1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of H2AFX in Leukemia Multidrug Resistant Cell Line
por: de Sousa Portilho, Adrhyann Jullyanne, et al.
Publicado: (2022) -
Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution
por: de Pinho Pessoa, Flávia Melo Cunha, et al.
Publicado: (2022)